|
Editorial: Snippets!
Looks like the middle class will also be taxed as well as the rich in order to pay for the government's runaway spending!
However, it appears that 40% of the population still do not pay any income taxes but will share in the benefits.
Not only are we looking at "redistribution of wealth," but also "redistribution of health"!
Rationing care to the elderly who have paid all their lives doesn't seem fair to accommodate many who have paid only minimally if at all. (40% of the U.S. population pays no taxes on earnings!)
It was reported that only 7% of members of Congress have agreed to "read" the healthcare bill prior to voting on it.
Our future is in the hands of those that don't seem to want to listen to American citizens or pay attention to those that will be paying for it!
Arrogance from our elected officials is starting to backfire on them!
Town hall meetings have changed from being poorly attended mini-pep rallies to down-to-earth question-and-answer sessions that many politicians do not know how to handle, and the public knows that the politicians' responses are gibberish and nonsensical!
For years, we have seen a steady move away from the things that made our nation great! History teaches us what happens when this occurs, if we will just pay attention!
Loyd V. Allen, Jr., PhD, RPh
Editor-in-Chief
|
|
CVS Caremark Merger under Investigation
Three U.S. senators have sent a letter to the Federal Trade Commission arguing that CVS Caremark Corp should be investigated, and the merger creating the combined drugstore chain and benefits manager should be examined.
The senators stated that the CVS Caremark merger has hurt Main Street pharmacies and created a heightened opportunity for anticompetitive conduct in the prescription drug market.
It was stated that patients who do not elect to fill prescriptions through Caremark's mail order business are charged higher copays. CVS Caremark denies these allegations.
Associated Press (7/31)
|
|
MARTINDALE: The Complete Drug Reference
36th Edition
Sweetman SC, ed.
London, UK: Pharmaceutical Press
2009; Price $516.00; 3,694 Pages; Hardback
If you are like me, it is great to see a new edition of a book hot off the press! Martindale's new 36th edition occupies two volumes, has 5,820 drug monographs, 146,000 preparations, 47,750 reference citations, and a list of 13,000 manufacturers.
This edition boasts 260 new monographs, with the chapters reorganized to better reflect the clinical use of drugs. Coverage of proprietary preparations has now expanded to 40 countries.
Needless to say, this edition is filled with information. Volume 1 contains monographs on drugs and ancillary substances, and Volume 2 contains preparations, directory of manufacturers, and the General Index.
The only negative is it is very large, and you generally need to use both volumes when sourcing a monograph; Volume 2 to find out where a monograph is, and Volume 1 to locate it. However, these minor negatives are far outweighed by the wealth of information contained.
A great book continuing a great tradition.
|
